Since 1966, D-Penicillamine has been used in the management of scleroderma. However, its therapeutic usefulness has been limited by a high incidence of a variety of adverse reactions. Cholestatic jaundice secondary to D-Penicillamine administratiori has been reported infrequently. We have experierced a case of acute chotestatic jaundice in a patient with scleroderma treated with D- Fenicillamine. We have encountered a patients who recovered from this complication whn D Penicillamine therapy was withdrawn. Literature was re!iewed briefly.